Reizdarmsyndrom – neue Entwicklungen

Schlüsselwörter

Reizdarmsyndrom - irritables Kolon - Obstipation - Blähungen - S3-Leitlinie

Keywords

irritable bowel syndrome - obstipation - abdominal bloating - guidelines

• Literatur

• 1 Allescher H-D, Storr M. Is irritable bowel syndrome a rhinitis of the gut?. Gastroenterology 2011; 140: 2132-2136
• 2 Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?. Ther Adv Gastroenterol 2012; 5: 261-268
• 3 Böhm SK, Kruis W. Die Germanen bringen Rom zu Fall – das Reizdarmsyndrom Stand 2011. Gastroenterologie up2date 2011; 7: 267-296
• 4 Brandt LJ, Chey WD, Foxx-Orenstein AE et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1-S35
• 5 Frieling T, Schemann M, Pehl C. Das Reizdarmsyndrom – eine Fehlbezeichnung?. Z Gastroenterol 2011; 49: 577-578
• 6 Houghton LA. Bloating in constipation: relevance of intraluminal gas handling. Best Pract Res Clin Gastroenterol 2011; 25: 141-150
• 7 Issa B, Wafaei NA, Whorwell PJ. Abdominal bloating and distension: what is the role of the microbiota. Dig Dis Sci 2012; 57: 4-8
• 8 Jiang X, Locke 3rd GR, Choung RS et al. Prevalence and risk factors for abdominal bloating and visible distention. Gut 2008; 57: 756-63
• 9 Layer P, Andresen V, Pehl C et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011; 49: 237-293
• 10 Longstreth DF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
• 11 Menees SB, Maneerattannaporn M, Kim HM et al. The efficacy and safety of rifaximin for the irritable bowel syndrome. Am J Gastroenterol 2012; 107: 28-35
• 12 Müller-Lissner S. Reizdarm. Gastroenterologie up2date 2010; 6: 113-122
• 13 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 2012; 5: 69-100
• 14 Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl Med J 2011; 22-32
• 15 Pimentel M, Morales W, Chua K et al. Effects of Rifixamin Treatment and Retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011; 56: 2067-2072
• 16 Quigley EMM. Prucalopride: safety, efficacy and potential. Ther Adv Gastroenterol 2012; 5: 23-30
• 17 Schmulson M, Chang L. Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther 2011; 33: 1071-1086
• 18 Shim L, Hansen RD, Prott M et al. Altered temporal characteristics of the rectoanal inhibitory reflex in patients with abdominal distension. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1343-1346
• 19 Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-1798
• 20 Staudacher HM, Lomer C, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142: 1510-1518
• 21 Staudacher HM, Whwlan K, Irving PM et al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 2011; 487-495
• 22 Sullivan SN. Functional abdominal bloating with distension. ISRN Gastroenterology 2012; 721820: 1-5
• 23 Weinstock RB. Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome. Dig Dis Sci 2011; 56: 3389-3390
• 24 Whorwell PJ. Unraveling functional abdominal bloating and distension: the role of thoraco-abdominal accommodation and a physical sign to aid its detection. Neurogastroenterol Motil 2012; 24: 301-304